henhaobio
Sign in

bioRxivPharmacology & ToxicologyPreprint

A benzoxazolylurea inhibits VraS and enhances antimicrobials against vancomycin intermediate-resistant Staphylococcus aureus

A. Sarkar, M. H. Abdelaziz, E. P. Heckler, L. Ali, B. Cagle-White, S. Bhattarai, N. Smith, R. A. Coover

PDFDOI

Abstract

Vancomycin intermediate-resistant Staphylococcus aureus (VISA) is a pathogen of concern. VraS, a histidine kinase, facilitates the VISA phenotype. Here, we reveal a benzoxazolylurea that directly inhibits VraS and enhances vancomycin to below the clinical breakpoint against an archetypal VISA strain. To the best of our knowledge, this is the first direct VraS inhibitor ever reported that shows significant enhancement of vancomycin against VISA.

Reproducibility ledger

Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.

Sign in to file a reproducibility report.

Similarity Map
SelectedSame fieldCross-field
THISAntinori '25Ali '25Maciunas '23Boudrioua '25Tan '18Mediati '23
76% semantic matchBiochemistry
Melisa B. Antinori, David Sychantha, Kalinka K. Koteva+4 more·bioRxiv·Jan 23, 2025